Alcoholic fatty liver is caused by long-term alcoholism, which leads to liver damage and inability to metabolize fat normally, thus leading to fat accumulation in the liver. Non-alcoholic fatty liver is caused by other reasons, such as obesity, diabetes, high cholesterol and so on.
Fatty liver usually has no obvious symptoms, but long-term existence may lead to liver function damage, liver fibrosis and even cirrhosis. Therefore, early detection and treatment are very important. Treatment methods include improving eating habits, losing weight, abstaining from alcohol and other measures. In severe cases, medication or surgery may be needed.
The latest research shows that metabolic surgery can obviously reduce patients' weight and is one of the long-term effective methods. However, not everyone can do metabolic surgery. Only patients who meet the surgical indications can receive surgical treatment, and the surgical treatment itself is traumatic, and the changes brought to the patient's body structure are irreversible for life. Some patients need to take vitamin supplements for life after surgery, so the popularity of this kind of surgery in domestic fatty liver patients is not high.
Fortunately, in recent years, in addition to metabolic surgery, endoscopic interventional therapy has begun to emerge in the field of fatty liver treatment. "Gastric bypass stent system" is an advanced new technology, which has the advantages of being more minimally invasive, easier to operate, not damaging human structure, being removable, and being re-implanted. It can be used as an intermediate means between medical treatment and metabolic surgery, and provides a new weight-losing method for patients who cannot tolerate or are unwilling to undergo surgery. The existing research results show that obese patients with nonalcoholic fatty liver can significantly lose weight and improve liver steatosis, liver enzymes, insulin resistance and metabolic parameters [1]. Patients with fatty liver can go to the Nutrition Department/Gastroenterology Department of 3A Hospital for a comprehensive examination to find a treatment path that is most suitable for them ~
References:
[ 1]? Ren M, Zhou X, Yu M, Cao Y, Xu C, Yu C, Ji F. Prospective study of a new endoscopic duodenal-jejunal bypass sleeve in obese patients with nonalcoholic fatty liver disease (with video) . Dig Endosc. 2022 Jul 23. doi: 10. 1 1 1 1/den. 14409. Epub ahead of print. PMID: 35869797.